The clinical responses to targeted drugs are often transient and do not always translate into meaningful overall survival due to the development of resistance. We discuss here that the greater power of drug resistant cells can be associated with significant newly-acquired vulnerabilities that can be exploited therapeutically.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276853 | PMC |
http://dx.doi.org/10.1080/23723556.2018.1509488 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!